Age: Addressing a Blind Spot in Cancer Care
GET TO KNOW DR. ANNALIESA ANDERSON, HEAD OF BACTERIAL VACCINES
PROFESSOR JOE SCHMITT TALKS TICK-BOURNE ENCEPHALITIS
HOW ARE VACCINES DEVELOPED?
WHAT YOU NEED TO KNOW ABOUT COVID-19
Darmstadt, Germany, and New York, US, June 22, 2020 – Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency (EMA) has validated for review the Type II variation application for BAVENCIO® (avelumab) for first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC). With this validation, the application is…